Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE
William V. Bobo, Jennifer L. Vande Voort, Paul E. Croarkin, et al.
Depression and Anxiety (2016) Vol. 33, Iss. 8, pp. 698-710
Open Access | Times Cited: 115

Showing 1-25 of 115 citing articles:

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)
Maurizio Fava, Marlene P. Freeman, Martina Flynn, et al.
Molecular Psychiatry (2018) Vol. 25, Iss. 7, pp. 1592-1603
Open Access | Times Cited: 351
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Anees Bahji, Gustavo Vázquez, Carlos A. Zarate
Journal of Affective Disorders (2020) Vol. 278, pp. 542-555
Open Access | Times Cited: 292
Ketamine Treatment and Global Brain Connectivity in Major Depression
Chadi G. Abdallah, Lynnette A. Averill, Katherine A. Collins, et al.
Neuropsychopharmacology (2016) Vol. 42, Iss. 6, pp. 1210-1219
Open Access | Times Cited: 271
The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
Chadi G. Abdallah, Gerard Sanacora, Ronald S. Duman, et al.
Pharmacology & Therapeutics (2018) Vol. 190, pp. 148-158
Open Access | Times Cited: 198
A historical review of antidepressant effects of ketamine and its enantiomers
Wei Yan, Lijia Chang, Kenji Hashimoto
Pharmacology Biochemistry and Behavior (2020) Vol. 190, pp. 172870-172870
Open Access | Times Cited: 140
Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability
Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Jan Spijker, et al.
The Lancet Psychiatry (2022) Vol. 9, Iss. 11, pp. 907-921
Open Access | Times Cited: 92
Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial
Dawn F. Ionescu, Kate H. Bentley, Matthias Eikermann, et al.
Journal of Affective Disorders (2018) Vol. 243, pp. 516-524
Closed Access | Times Cited: 149
Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials
Joanna Kryst, Paweł Kawalec, Alicja Mikrut Mitoraj, et al.
Pharmacological Reports (2020) Vol. 72, Iss. 3, pp. 543-562
Open Access | Times Cited: 111
CHALLENGES OF TREATMENT-RESISTANT DEPRESSION
James Paul Pandarakalam
Psychiatria Danubina (2018) Vol. 30, Iss. 3, pp. 273-284
Open Access | Times Cited: 106
Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment
Chadi G. Abdallah, Christopher L. Averill, Ramiro Salas, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2017) Vol. 2, Iss. 7, pp. 566-574
Open Access | Times Cited: 101
Major depressive disorder: Validated treatments and future challenges
Rabie Karrouri, Zakaria Hammani, Roukaya Benjelloun, et al.
World Journal of Clinical Cases (2021) Vol. 9, Iss. 31, pp. 9350-9367
Open Access | Times Cited: 101
Continuation phase intravenous ketamine in adults with treatment-resistant depression
Jennifer L. Vande Voort, Robert J. Morgan, Simon Kung, et al.
Journal of Affective Disorders (2016) Vol. 206, pp. 300-304
Closed Access | Times Cited: 87
Intranasal Esketamine (SpravatoTM) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant.
Rebecca Bahr, Alicia Quirós López, Jose A Rey
PubMed (2019) Vol. 44, Iss. 6, pp. 340-375
Closed Access | Times Cited: 79
The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research
Meysam Amidfar, Marie Woelfer, Gislaine Z. Réus, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2019) Vol. 94, pp. 109668-109668
Closed Access | Times Cited: 75
Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review
Emma I Kopra, Valeria Mondelli, Carmine M. Pariante, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 8, pp. 934-945
Open Access | Times Cited: 57
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
Anees Bahji, Carlos A. Zarate, Gustavo Vázquez
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 853-866
Open Access | Times Cited: 38
Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
Cameron N. Calder, Angela T.H. Kwan, Kayla M. Teopiz, et al.
Journal of Affective Disorders (2024) Vol. 356, pp. 753-762
Closed Access | Times Cited: 8
The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update
William V. Bobo
Mayo Clinic Proceedings (2017) Vol. 92, Iss. 10, pp. 1532-1551
Open Access | Times Cited: 85
Investigational drugs in recent clinical trials for treatment-resistant depression
Ricardo P. Garay, Carlos A. Zarate, Thomas Charpeaud, et al.
Expert Review of Neurotherapeutics (2017) Vol. 17, Iss. 6, pp. 593-609
Open Access | Times Cited: 71
Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder
Joanna Kryst, Paweł Kawalec, Andrzej Pilc
Expert Opinion on Pharmacotherapy (2019) Vol. 21, Iss. 1, pp. 9-20
Closed Access | Times Cited: 59
The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder
Konstantinos Ν. Fountoulakis, Lakshmi N. Yatham, Heinz Grunze, et al.
The International Journal of Neuropsychopharmacology (2019) Vol. 23, Iss. 4, pp. 230-256
Open Access | Times Cited: 57
Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant
Saurabh S. Kokane, Ross J. Armant, Carlos A. Bolaños‐Guzmán, et al.
Behavioural Brain Research (2020) Vol. 384, pp. 112548-112548
Open Access | Times Cited: 51
Ketamine for Bipolar Depression: A Systematic Review
Anees Bahji, Carlos A. Zarate, Gustavo Vázquez
The International Journal of Neuropsychopharmacology (2021) Vol. 24, Iss. 7, pp. 535-541
Open Access | Times Cited: 47
Pharmacotherapy
Anna Feeney, George I. Papakostas
Psychiatric Clinics of North America (2023) Vol. 46, Iss. 2, pp. 277-290
Closed Access | Times Cited: 17
Mitochondrial Metabolism in Major Depressive Disorder: From Early Diagnosis to Emerging Treatment Options
Ane Larrea, Laura Sánchez-Sánchez, Eguzkiñe Díez-Martín, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1727-1727
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top